Sutro Biopharma, Inc. (STRO)
15.87
+0.16
(+1.02%)
USD |
NASDAQ |
Sep 25, 15:30
Sutro Biopharma Cash from Operations (TTM) : -145.17M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -145.17M |
| March 31, 2026 | -151.61M |
| December 31, 2025 | -177.23M |
| September 30, 2025 | -222.53M |
| June 30, 2025 | -248.86M |
| March 31, 2025 | -194.68M |
| December 31, 2024 | -191.54M |
| September 30, 2024 | -105.73M |
| June 30, 2024 | -74.72M |
| March 31, 2024 | -115.37M |
| December 31, 2023 | -111.62M |
| September 30, 2023 | -149.55M |
| June 30, 2023 | -50.20M |
| March 31, 2023 | -22.19M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.549M |
| September 30, 2022 | 5.833M |
| June 30, 2022 | -84.43M |
| March 31, 2022 | -86.50M |
| December 31, 2021 | -81.68M |
| September 30, 2021 | -78.98M |
| June 30, 2021 | -72.26M |
| March 31, 2021 | -79.50M |
| December 31, 2020 | -67.80M |
| September 30, 2020 | -62.08M |
| June 30, 2020 | -60.51M |
| March 31, 2020 | -63.61M |
| December 31, 2019 | -65.02M |
| September 30, 2019 | -57.80M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Upstream Bio, Inc. | -136.34M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |
| Savara, Inc. | -110.38M |